Evotec (EVO) Fundamentals 2026 — Revenue Analysis | SniperIQ
Evotec (EVO) is a DE-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of $699M, trading at
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Evotec's market cap?
Evotec (EVO) has a market capitalization of approximately $699M, trading at
What is Evotec's P/E ratio?
Evotec's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Evotec?
Evotec runs a net profit margin of -26.0%, a gross margin of 11.5%, and an operating margin of -13.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Evotec generate?
Evotec reported revenue of €757M for fiscal year 2025, with net income of -€99M and earnings per share (EPS) of -0.28. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Evotec pay a dividend?
Evotec does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Evotec financially healthy?
Evotec carries a debt-to-equity ratio of 0.55x and a current ratio of 1.68x, with a market beta of 1.31. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Evotec a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Evotec (EVO) the key facts are: market cap $699M, revenue €757M, 52-week range 1.94-4.42. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Evotec's full fundamentals live
Get Evotec's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.